These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 1490658

  • 1. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.
    Silbergeld A, Klinger B, Schwartz H, Laron Z.
    Horm Res; 1992; 37(4-5):160-4. PubMed ID: 1490658
    [Abstract] [Full Text] [Related]

  • 2. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
    Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB.
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of insulin-like growth factor I on the thyroid axis in patients with Laron-type dwarfism and healthy subjects.
    Klinger B, Ionesco A, Anin S, Laron Z.
    Acta Endocrinol (Copenh); 1992 Dec; 127(6):515-9. PubMed ID: 1362849
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.
    Laron Z, Suikkari AM, Klinger B, Silbergeld A, Pertzelan A, Seppälä M, Koivisto VA.
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):351-8. PubMed ID: 1280392
    [Abstract] [Full Text] [Related]

  • 8. Prolactin responses to hypoglycemia and thyrotropin-releasing hormone in anorexia nervosa.
    Karibe C, Tamai H, Kiyohara K, Kobayashi N, Nakagawa T.
    Acta Psychiatr Scand; 1988 Oct; 78(4):442-7. PubMed ID: 3147579
    [Abstract] [Full Text] [Related]

  • 9. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R.
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
    Laron Z, Klinger B, Erster B, Anin S.
    Lancet; 1988 Nov 19; 2(8621):1170-2. PubMed ID: 2903379
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.
    Laron Z, Klinger B, Erster B, Silbergeld A.
    Acta Endocrinol (Copenh); 1989 Oct 19; 121(4):603-8. PubMed ID: 2800930
    [Abstract] [Full Text] [Related]

  • 18. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.
    Hayashi S, Okimura Y, Yagi H, Uchiyama T, Takeshima Y, Shakutsui S, Oohashi S, Bowers CY, Chihara K.
    Endocrinol Jpn; 1991 Feb 19; 38(1):15-21. PubMed ID: 1915110
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.